 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cingulate reports Q4 EPS net loss $6.9M

$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE...

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

CEO Shane Schaffer says a ripple from the collapse of Silicon Valley Bank set in motion a tough financial year for his Kansas City, Kansas, company...

Cingulate CEO talks about the pharmaceutical company's road ahead after tough 2023

KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR ) drug delivery platform...

Cingulate to Participate in Benzinga All Live Access Event

Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and TechnologyKANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Cingulate to Attend DCAT Week 2024 in New York City

Announcement Follows Recent Public Offering and Successful Capital Raising ActivityKANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company...

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) ( Cingulate, the Company, we, our or us ), a biopharmaceutical company utilizing its proprietary Precision...

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate prices 3.75M shares at $2.00 in public offering

KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) ( Cingulate, the Company, we, our or us ), a biopharmaceutical company utilizing its proprietary Precision...

Cingulate Announces Pricing of $7.5 Million Public Offering

KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR ) drug delivery platform...

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.

Volume (M)	152,633.00
52-Wk High	$23.80
52-Wk Low	$0.75

CING Cingulate Inc

About

Feed

News

Fundamentals